These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 8941924

  • 1. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S, Ynares C, Dummer S, Helderman JH.
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
    Abraham KA, O'Kelly P, Spencer S, Hickey DP, Conlon PJ, Walshe JJ.
    Ren Fail; 2008 Sep; 30(2):141-6. PubMed ID: 18300112
    [Abstract] [Full Text] [Related]

  • 6. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 7. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 8. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar 02; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 9. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 02; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 10. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP, Handa A, Tan L, Devaney A, Hughes D, Mason P, Friend PJ, Darby CR.
    Transpl Int; 2003 Oct 02; 16(10):726-9. PubMed ID: 12827230
    [Abstract] [Full Text] [Related]

  • 11. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Oct 02; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 02; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N, Holman MJ, Yang HC.
    Clin Transplant; 1997 Dec 02; 11(6):633-9. PubMed ID: 9408699
    [Abstract] [Full Text] [Related]

  • 16. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC.
    N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384
    [Abstract] [Full Text] [Related]

  • 17. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A.
    Bone Marrow Transplant; 2004 May 13; 33(9):931-5. PubMed ID: 15034541
    [Abstract] [Full Text] [Related]

  • 18. Gancyclovir prophylaxis in high risk patients.
    Campino A.
    Transplant Proc; 2005 Dec 13; 37(10):4311-2. PubMed ID: 16387106
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R.
    Clin Transplant; 2004 Apr 13; 18(2):179-85. PubMed ID: 15016133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.